NEWS & INSIGHTS

Since the early 2000s, early economic models have been used by many developers as a best practice to maximize development through clinical trial design and commercial success. Early economic models are similar to HTA models in that they assess the direct and indirect costs and consequences of using a new therapy. Based off experience, early health economic models have been particularly useful in three major areas.

• Assessing commercial viability
• Developing clinical trial design and evidence-generation strategy
• Planning for launch preparedness

Ivar Jensen (VP, Precisionheor) is joined by Phil Cyr (SVP, Precision Value & Health) to provide insight on this in “Early Health Economic Models in Gene and Cell Therapy to Inform Clinical Trial Design and Optimize Commercialization Efforts“.

CLICK HERE to read the full article

We’re excited to announce that two of our Precision colleagues have been named to MM+M’s 40 Under 40 this year! Congratulations to Ashwin Athri, EVP, Managing Director, PRECISIONxtract, and Isabella Sergio, EVP, Managing Director, PRECISIONvalue. Now in its fourth year, 40 Under 40 honors the industry’s best-regarded young talent. We look forward to celebrating with Ashwin and Isabella, and all the other honorees, on February 16.

Precision’s Dr. Dominic Galante will moderate the Quality Conversations Breakfast session on Day 2 of the NCQA Health Innovation Summit. “Digital Reshaping of the Diabetes Health-Care Ecosystem” will explore the promise of leveraging patient-generated data from CGMs to improve diabetes care, health equity, and the potential to augment diabetes quality measures that are reported and tracked by quality organizations. November 1 at 7:30AM ET.

Learn how to make your brands’ market access a top advantage over the competition. Join PRECISION’s Jon Bambalas, Jeff Becker and Thad Nowakowski at this year’s Managed Markets & Account Management Strategies Conference for “Make Market Access Your Brand’s Super Power,” October 27 at 9:30 AM CT.

REGISTER HERE!

Patient support programs, like HUB services, Patient Assistance Programs (PAP), Bridge programs or copay support, have become increasingly important in making prescription drugs more affordable and accessible. Yet an IQVIA study found that 31% of patients abandon their prescription if a coupon is not available compared with only 12% of new patients walked away from their prescriptions if a copay coupon was available to them.

Prescription abandonment continues to be a significant issue.

In this insightful webinar from PRECISIONxtract, you’ll hear how life science brand leaders can leverage EHR systems to dramatically increase successful enrollment for patient support programs.

Attendees will hear about:

• What are the primary barriers and challenges to patient support program enrollment?
• How to take advantage of EHR functionality for patient support program enrollment (most of the information needed to enroll patients already resides in the EHR!)
• Advantages of optimizing EHR for enhanced patient support (accelerated ordering and external testing, increased adherence and more)
• And how this technology can be used beyond patient support program enrollment

Join us for this unique, solution-based discussion— a great fit for pharma manufacturers looking to get their brands’ patient resources in front of HCPs where those HCPs are in the moment of care — inside the EHR!

WATCH ON DEMAND HERE!

At this years Meeting on the Mesa’s conference, Anshul Mangal: President (Precision ADVANCE and Project Farma) sat down with leading industry experts to discuss the future of cell and gene therapies.

This panel, sponsored by Precision ADVANCE, will feature insights from industry leaders on the future of advanced therapies including innovations in clinical trials, going from treating rare diseases to prevalent conditions, and implementing next-generation gene-editing technologies. The panelists will also discuss manufacturing and talent bottlenecks and the evolution of reimbursement payment models.

Moderated by Anshul Mangal (President of Project Farma & Precision ADVANCE), this discussion will feature insights from Stewart Abbot: (Chief Scientific Officer, Turnstone Biologics), Andrew Knudten: (Chief Operating Officer, Jaguar Gene Therapy), Laura Lande-Diner: (Chief Business Officer, Satellite Bio), Robert Peters: (Chief Scientific Officer, Ensoma), and Deborah Phippard: (Chief Scientific Officer, Precision for Medicine).

WATCH ON-DEMAND HERE